Leap, a full-stack international student mobility platform, has raised $65 million through a mix of primary and secondary ...

H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

Overseas education company Leap has raised USD $65 million in Series E funding, bringing its total equity backing to ...

Work reveals new ways to understand and manipulate electrons in materials. MIT physicists, in collaboration with colleagues, ...

Shares of Leap Therapeutics slid after disappointing initial data from two mid-stage clinical trials of its oncology treatment, resulting in the discontinuation of one clinical program.

Leap Therapeutics has come crashing down to earth. The biotech axed plans to advance into phase 3 in gastric cancer on the basis of midstage data, sending its stock down 60% to below $1, but it is ...

H.C. Wainwright downgraded Leap Therapeutics (LPTX) to Neutral from Buy without a price target after the company presented clinical data ...

Further to Microsoft's pledge to make Xbox more profitable, one of their biggest franchises is arriving on PlayStation soon.